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Background: Nicotine is rapidly absorbed from cigarette smoke and therefore induces a number of chronic
illnesses with the widespread use of tobacco products. Studies have shown a few cerebral metabolites modified by
nicotine; however, endogenous metabolic profiling in brain has not been well explored.
Results: H NMR-based on metabonomics was applied to investigate the endogenous metabolic profiling of brain
hippocampus, nucleus acumens (NAc), prefrontal cortex (PFC) and striatum. We found that nicotine significantly increased
CPP in mice, and some specific cerebral metabolites differentially changed in nicotine-treated mice. These modified
metabolites included glutamate, acetylcholine, tryptamine, glucose, lactate, creatine, 3-hydroxybutyrate and
nicotinamide-adenine dinucleotide (NAD), which was closely associated with neurotransmitter and energy
source. Additionally, glutathione and taurine in hippocampus and striatum, phosphocholine in PFC and glycerol
in NAc were significantly modified by nicotine, implying the dysregulation of anti-oxidative stress response and
membrane metabolism.
Conclusions: Nicotine induces significant metabonomic alterations in brain, which are involved in
neurotransmitter disturbance, energy metabolism dysregulation, anti-oxidation and membrane function disruptions,
as well as amino acid metabolism imbalance. These findings provide a new insight into rewarding effects of nicotine
and the underlying mechanism.
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Nicotine is considered as the major addictive component
of tobacco smoke, resulting in addiction in humans
[1,2]. According to the World Health Organization,
nicotine addiction is a global health problem affecting
one-third of the population [3]. Some highly addicted
smokers attempt to quit smoking; however, only 3–5%
are successful without the use of nicotine replacement
therapies, and no more than one-third are successful
with them [4]. It is known that the addiction behavior
caused by nicotine is involved with rewarding effects of
nicotine. Therefore, much effort has been carried out to* Correspondence: xbcen@scu.edu.cn
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unless otherwise stated.explore the mechanism of rewarding effects of nicotine.
Nicotine stimulates the brain areas containing nicotinic
acetylcholine receptor (nAChR) subunits, leading to the
release of a variety of neurotransmitters [5]. Ventral teg-
mental area (VTA) of the midbrain, which projects to
the prefrontal cortex (PFC), limbic, striatal structures,
and nucleus accumbens (NAc), contributes to nicotine
intake and reinforcement [6,7]. However, these studies
have only focused on certain AChR subunits and/or
neurotransmitters, which have already been known to
participate in rewarding effects of nicotine, lacking en-
dogenous metabolic profiling in a global view. We won-
dered if the rewarding effects of nicotine on the brain
were related to some endogenous metabolites. There-
fore, we tried to detect changes of metabolites in numer-
ous brain regions of mice after nicotine treatment.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has been widely applied in neuropsychiatric research
field, such as drug addiction, motor neuron disease,
schizophrenia and Parkinson’s disease [8,9]. Additionally,
multivariate analysis of metabolic profiles reveal that
smoking is associated with plasmalogen-deficiency disor-
ders [10]. Unlike genomics, transcriptomics and proteo-
mics which indicate what may happen, metabonomics
measure all metabolites, which determine the state of
the pathophysiology of organism and have the potential
to identify related biomarkers. Nuclear magnetic reson-
ance (NMR) is one of the analytical methods in metabo-
lomics research and has been widely applied to explore
multiple metabolic changes in brain tissues [11,12].
For example, 1H NMR-based metabonomics shows the
neurotransmitter disturbance in brain NAc and stri-
atum of cocaine-treated rats [13]. Neurotransmitter
and purine metabolic pathway are likely affected by ad-
dictive substances, including morphine and cocaine
[14]. Therefore, 1H NMR-based metabonomics was ap-
plied to explore the changes of metabolites in brain
after nicotine treatment in our study.
Conditioned place preference (CPP) is a naturalistic
model of addictive behavior. CPP measures an animal’s
preference for a particular place in its environment, which
becomes closely contacted with a rewarding stimulus and
assumes the rewarding effects of the stimulus [15]. CPP
had been selected to explore the rewarding effects of nico-
tine in many studies. In our study, CPP was chosen to ex-
plore nicotine-induced rewarding effects [16,17].
In the present study, we developed CPP induced by
nicotine in C57BL/6 J mice and applied 1H NMR-based
metabonomics coupled with principal component ana-
lysis (PCA), partial least squares (PLS) and orthogonal
signal correction (OSC) to examine the changes of meta-
bolic profile in the brain hippocampus, NAc, PFC and
striatum. We found that nicotine can result in neuro-
transmitter disturbance, oxidative stress alteration, mito-
chondria dysregulation, membrane disruption, energy
metabolism imbalance, and amino acid disorder. Our
findings provide a new insight into the neurobiological




Nicotine hydrogen tartrate (doses expressed as base) was
purchased from Sigma (Beijing, China). Nicotine was
dissolved in 0.9% sterile saline before use.
Animals and administration
C57BL/6 J mice (16 male, 8-12 weeks old) were kept in
clear plastic cages with five per cage at under a 12/12 h
light–dark cycle in room temperature (21 ± 5°C) with arelative humidity of 55 ± 15% and an air change rate of
8–10 changes/hour, and given food and water. The ani-
mals were acclimatized for 7 days before experiment.
This study was carried out in accordance with the guide-
lines established by the Association for Assessment and
Accreditation of Laboratory Animal Care. The protocols
were approved by the Committee on the Ethics of Ani-
mal Experiments of National Chengdu Center for Safety
Evaluation of Drugs, West China Hospital of Sichuan
University (Protocol number IACUC-S200909-P001).
All surgery was performed under sodium pentobarbital
anesthesia, and all efforts were made to minimize
suffering.
Nicotine CPP
Place conditioning studies were conducted using a shut-
tle box which was composed of three distinct chambers
including two large conditioning chambers and a small
central start chamber. During pretest phase, on day 0,
mice were placed in the central chamber, and allowed to
move the apparatus for 15 min. The time spent in each
chamber was recorded. Mice with a chamber bias
greater than 75% were dropped from studies and un-
biased mice were randomly assigned to two groups in-
cluding control group (0.9% sodium chloride only) and
nicotine group (0.5 mg/kg nicotine). Nicotine and saline
were administrated by subcutaneous injection (s.p). On
days 1–3, in nicotine group, mice were given one injec-
tion of nicotine (0.5 mg/kg) on the non-preferred cham-
ber by closing the removable wall for a period of 15 min
and one injection of saline on the preferred chamber
each day for a period of 15 min (one in the morning and
one in the afternoon 4 hours later in a counterbalanced
manner); moreover, in control group, nicotine was re-
placed by saline and the rest procedures were as de-
scribed above. During posttest phase, on the fifth day,
CPP was tested. Each mouse was allowed to move freely
between all the chambers for 15 min and the time spent
in each chambers was measured. Data were expressed as
the changed time in posttest minus the changed time in
pretest, and the changed time is time spent in the pre-
ferred chamber minus time spent in the non-preferred
chamber. And each group was presented as mean ± SD.
One-way analysis of variance (ANOVA) followed by
Tukey post hoc test was used to determine statistical
significance.
Preparation of brain extracts
Mice were sacrificed by cervical dislocation within
30 minutes after the end of CPP posttest. Specimens of
bilateral brain hippocampus, NAc, PFC and striatum
(~30-100 mg) were dissected immediately, snap-frozen
in liquid nitrogen, and stored at −80°C until NMR
spectroscopic analysis. The preparation of the brain
Li et al. BMC Neuroscience 2014, 15:32 Page 3 of 11
http://www.biomedcentral.com/1471-2202/15/32samples was based on the previous studies [18,19]. The fro-
zen tissue was added into 0.5 ml chloroform and homoge-
nized at 4°C. The supernatant was preserved to lyophilize
for about 36 hours after centrifugation at 10, 000 g for
10 min at 4°C. Dried extracts after lyophilization were
added into 480 μl D2O, including 20 μl0.25 mM sodium
(3-trimethylsilyl)-2, 2, 3, and 3-tetradeuteriopropionate
(TSP), and then transferred into 5 mm NMR tubes for
1H NMR detection.
Solution 1H NMR Spectroscopy
1H NMR spectral data were acquired on a Bruker-Av II600
MHz spectrometer(Bruker Co, Rheinstetten, Germany)at
300 K.A standard (1D) Carr-Purcell-Meiboom-Gill (CPMG)
pulse sequence was used to acquire a one-dimensional
spectrum and suppress the water signal with a relaxation
delay of 5 s. Typically, 64 free induction decays (FIDs) were
collected into 64 k data points over a spectral width of
8992.8 Hz with a relaxation delay of 5 s and 0.91 s to total
acquisition time. The FIDs were weighted by an exponential
function with a 0.3-Hz line-broadening factor prior to Fou-
rier transformation.
Data reduction and pattern recognition analysis
All NMR spectra were automatically reduced to 218 seg-
ments, each with a 0.04 ppm width for a spectral win-
dow ranging from 9.5 to 0.2 ppm using MestRe-c 2.3
software (http://qobrue.usc.es/jsgroup/MestRe-c). The
area for each segmented region was calculated. The
segments of δ 4.6-5.1 ppm in spectra were removed to
exclude the influence of the residual water resonance.
The datasets were mean-centered prior to PCA, PLS
and OSC analysis by the SIMCA package. PCA distin-
guished the characteristic variable (metabolic signals)
or the outlier from the group by statistical method.
Partial least squares (PLS), one of the most popular su-
pervised pattern recognition (PR) methods, was served
as the regression extension of principal component
analysis (PCA) which is an unsupervised method [20].
Orthogonal signal correction (OSC) can filter unwanted
variation from near-infrared spectral data. In order to
strengthen the performance of subsequent multivariate
pattern-recognition analysis and reinforce the predictive
ability of the model, OSC was applied to optimize the sep-
aration in NMR-based metabonomic studies [21]. The
variable importance plot (VIP) values and corresponding
loadings for PLS models using OSC transformed data set
were applied to identify the variable contribution to the
position of spectra that were altered after drug treatment.
1H NMR chemical shifts and assignments of endogenous
metabolites were conducted according to the previous lit-
eratures and the Human Metabolome Database (http://
www.hmdb.ca/). Above methods have been well recog-
nized and widely used in metabonomics [22,23].Results
Nicotine-induced CPP
Each group spent almost the same time on the initially
non-preferred side, indicating that there were no basal
differences between groups. The group receiving 0.5 mg/kg
dose of nicotine spent significantly more time in the
nicotine-paired chamber on the posttest day than the pre-
test day (P < 0.05)(Figure 1A). This result showed that in-
jection of nicotine was sufficient to increase CPP in
C57BL/6 J mice.
NMR spectra and PLS-DA analysis
Representative 1H NMR spectra of the water extracts of
the striatum in control and nicotine groups were shown
in Figure 1B with major metabolites in the integrate re-
gions assigned. Visual inspection of 1H NMR spectra
displayed distinctions between control and nicotine
groups. To further investigate these distinctions, we uti-
lized PCA, PLS and OSC to uncover the latent biochem-
ical information from brain hippocampus, NAc, PFC
and striatum. We firstly applied PCA as an unsupervised
PR method to analyze the data sets of the 1H NMR
spectra. Subsequently, we augmented this separation by
using PLS, as a supervised PR method. However, afore-
mentioned two PR methods displayed no clear separation
in the brain NMR spectra for the first two principal com-
ponents (PCs) in each treated groups. Then, PLS model
following OSC was performed to further separate these
treated groups. Each brain region of treated groups
showed a significant differentiation in the PLS scores plots
after application of OSC-PLS model (Figure 2).
In order to reach a credible conclusion, the OSC-PLS
model was validated by a permutation method. The idea
of this validation was to compare the goodness of fit
(R2Y) and the predictability (Q2Y) of the original model
based on data. R2Y was mathematically reproduced var-
ies between 0 and 1, where 1 indicated a model with a
perfect fit. Q2Y values of >0.5 and >0.9 implied good and
excellent predictive abilities, respectively. In our study,
high values of R2Y and Q2Y in these PLS models were
displayed. For example, in striatum, R2Y was 0.985 and
Q2Y was 0.974, which forcefully indicated that OSC-PLS
model in our study had good or excellent fitness and
predictive abilities, thus being valid (Figure 3).
Metabolic changes in mice hippocampus, NAc, PFC and
striatum
To investigate metabolic changes of brain hippocampus,
NAc, PFC and striatum in control and nicotine groups, PLS
loading plots after application of OSC data filter was applied
to analyze 1H NMR data (Figure 4). In hippocampus, the
metabolites that predominantly contributed to the separ-
ation of two groups were glutamate, creatine, glutathione,
taurine, glucose and 1-methylhistidine (Figure 4A and
Figure 1 Scores of nicotine-induced conditioned place preference (A) and 600 MHz CPMG 1H NMR spectra of the striatum from mice
(B). (A) After repeated 0.5 mg/kg nicotine treatment, mice developed a significant preference for nicotine-paired side (n = 8, p < 0.05, F = 5.886);
(B) the upper is control group; the bottom one is nicotine group.
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tamate from hippocampus of nicotine group than control
(Figure 4A). Moreover, the 3.4 bucket indicated higher glu-
cose from NAc (Figure 4B and Table 2), but lower glucose
from PFC in nicotine-treated mice (Figure 4C and Table 3).
In striatum, creatine (3.04 ppm) of nicotine group showed
higher level than that of control (Figure 4D and Table 4).
Correspondingly, according to the VIP values (VIP ≥ 1) in
the OSC-PLS models, the differentially changed metabolites
in the hippocampus, NAc, PFC and striatum of mice were
identified and listed in Tables 1–4, respectively.
Metabolites changes in neurotransmitters
Compared with saline control, glutamate, tryptamine and
acetylcholine were significant altered in hippocampus,NAc and striatum in nicotine-treated mice. Glutamate
(2.08 ppm), a neurotransmitter, was reduced in hippocam-
pus and striatum but increased in NAc and PFC. Trypta-
mine (7.32 ppm), a precursor of 5-HT, was also increased
in NAc. Moreover, acetylcholine (3.24 ppm) was elevated
in striatum. The initial disturbances of neurotransmitters
are listed in Table 2 to Table 4, respectively.
Metabolites alterations in oxidative stress
In nicotine-treated mice, glutathione (3.8 ppm), an
antioxidant, was decreased in hippocampus (Table 1);
moreover, taurine (3.28 ppm), acting as a free radical
scavenger and possessing cytoprotective properties,
was significantly reduced in hippocampus and striatum
(Table 4).
Figure 2 PLS scores plots and OSC-PLS scores plots of brain regions from mice: (A) hippocampus; (B) NAc; (C) PFC; (D) striatum.
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caused by metabolites changes
Phosphocholine (4.16 ppm) and glycerol (3.64 ppm), mem-
brane ingredients, were markedly increased by nicotine
CPP paradigm, the former in PFC, the latter in NAc
(Tables 2 and 3). Moreover, NAA (4.4 ppm), a marker
of neuronal viability and metabolite synthesized in mito-
chondria, was increased distinctively in striatum (Table 4).
Metabolites variations related to energy metabolism
Several metabolites, including glucose, lactate, creatine,
acetone, 3-hydroxybutyrate and nicotinamide-adenine
dinucleotide (NAD), were significantly modified in cer-
tain brain regions of nicotine-treated mice (Tables 1–4).
For example, glucose (3.4 ppm) was markedly decreased
in hippocampus, PFC and striatum, but increased in
NAc. Creatine (3.04 ppm), which stores energy for the
cell by means of a phosphate covalent bond in a similar
manner to ATP/ADP, was decreased markedly in hippo-
campus but increased in striatum. It is known that lac-
tate provides an alternate energy source for brain. After
nicotine CPP paradigm, the increases in lactate (1.32 ppm)and 3-hydroxybutyrate were found in NAc. However, acet-
one (2.24 ppm), 3-hydroxybutyrate (1.2 ppm) and NAD
(8.84 ppm) were reduced in PFC.
Metabolites alterations associated with amino acid
The levels of several amino acids were altered in the four
brain regions of nicotine-treated mice, including glu-
tamic acid, lysine, isoleucine, phenylalanine, arginine and
cystine (Tables 1 and 4). Among these modified amino
acids, cystine (3.36 ppm) was significantly dropped in
hippocampus, PFC and striatum, but dramatically raised
in NAc. Lysine (1.36 ppm) displayed a decrease in hippo-
campus; however, lysine in striatum was increased. Phenyl-
alanine (3.12 ppm) in PFC and isoleucine (1.28 ppm) in
NAc were reduced by nicotine. Moreover, a reduction of
uracil (7.52 ppm) in PFC was obvious. These findings
imply that nicotine causes disruptions of amino acid me-
tabolisms in brain.
Discussion
Many studies have been performed to explore the mech-
anisms underlying nicotine-induced rewarding effects,
Figure 3 Validation plots of the PLS models after application of OSC: (A) hippocampus; (B) NAc; (C) PFC; (D) striatum.
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nomics not only is involved within the system biology
framework, but also provides a promising opportunity to
explore the molecular mechanisms of diseases [24,25].
The current experiment was designed to study the meta-
bolic profling of nicotine-induced CPP mice by applying
1H NMR-based metabonomic in four brain regions in-
cluding hippocampus, PFC, NAc and striatum. Interest-
ingly, we found that certain metabolites were markedly
altered by nicotine. The modified metabolites are corre-
lated with neurotransmitter disturbance, oxidative stress
alteration, mitochondria dysregulation, membrane dis-
ruption, energy metabolism imbalance as well as amino
acid disorder. We consider that the rewarding effect of
nicotine in mice may be closely associated with these
modified metabolites. In other words, changes in CPP
behavior may contribute to differences between controls
and nicotine-exposed animals in the metabolomic
analysis.
Disturbance in neurotransmitters
Nicotine, a biologically active substance, has widespread
pharmacological properties in the central and peripheralnervous systems. It has been shown that nicotine regulates
release of multiple neurotransmitters, including dopa-
mine, norepinephrine, serotonin, acetylcholine and amino
acids in various regions of rat brain such as the cortex,
hippocampus, NAc, striatum [26,27]. Repeated adminis-
tration of nicotine induces both behavioral sensitization
and alterations in dopamine and glutamate transmission
as well as glutamatergic synaptic plasticity [28,29]. Consid-
erable researches into the neurobiology of cocaine addic-
tion have displayed that glutamate plays a crucial role in
both the initiation and expression of addiction related be-
haviors [30,31]. In nicotine-induced CPP mice, glutamate
showed a low level in hippocampus and striatum, but dis-
played a high level in NAc and PFC. Considering that glu-
tamate not only affects glutamatergic synaptic plasticity
but also modulates initiation and expression of addiction
behaviors, we infer that altered glutamate equilibrium in
neurotransmitter signaling may participate in nicotine-
induced CPP in mice [32].
Acetylcholine, an endogenous agonist of nAChR, is
thought to modulate learning and memory by altering
the oscillatory rhythms that result from the interaction
of various hippocampal subregions [33,34]. In our study,
Figure 4 Comparison of brain region from mice between control group and nicotine group by applying PLS loading plots for the
region 9.4–5.1 and 4.6–0.2 ppm (218 segments) after application of OSC data filter; (A) hippocampus in control group and nicotine
group; (B) NAc in control group and nicotine group; (C) PFC in control group and nicotine group; (D) striatum in control group and
nicotine group.
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over, an increase of tryptamine, a precursor of 5-HT,
was displayed in NAc. Several preclinical studies suggest
that acetylcholine exerts a myriad of effects on the ad-
dictive process and that persistent changes to theTable 1 Summary of the variations from hippocampus
metabolites in mice
Metabolites Chemical shift Control-nicotine
(ppm) VIPa Loadingb
Glutamate 2.08 6.07 −0.433
Cystine 3.36 4.64 −0.287
Creatine 3.04 3.88 −0.229
Glutathione 3.8 3.37 −0.258
1-Methylhistamine 3.68 3.28 −0.241
Taurine 3.28 2.79 −0.2 18
2-Ketobutyric acid 2.76 2.71 −0.167
* 3.6 2.19 −0.159
Glucose 3.40 2.11 −0.021
Lysine 1.36 2.09 −0.163
aVariable importance in the projection (VIP ≥ 1) was obtained from OSC-PLS.
bLoading: the negative (−) value represents a decrease of the metabolite in
the second group of the subtitle (e.g.: Control→ Nicotine).
The symbol (*) represents a material which has not been identified.acetylcholine system induced by chronic drug use may
enhance the risk of relapse. We speculate that nicotine
can modify synaptic plasticity through altering neuro-
transmitter release, such as glutamate, acetylcholine and
tryptamine.Table 2 Summary of the variations from NAc metabolites
in mice
Metabolites Chemical shift Control-nicotine
(ppm) VIPa Loadingb
Glutamate 2.08 5.02 +0.369
Isoleucine 1.28 4.46 +0.331
1 -Methyihistamine 3.68 2.99 +0.223
Cystine 3.36 2.96 +0.068
2-Ketobutyric acid 2.76 2.24 +0.162
Lactate 1.32 2.11 +0.148
Tryptamine 7.32 2.09 +0.155
Glycerol 3.64 2.04 +0.153
Glucose 3.40 1.92 +0.066
3 -Hydroxybutyric acid 1.20 1.90 +0.142
aVariable importance in the projection (VIP ≥ 1) was obtained from OSC-PLS.
bLoading: the positive (+) value represents an increase of the metabolite in the
second group of the subtitle (e.g.: Control→ Nicotine).
Table 3 Summary of the variations from PFC metabolites
in mice
Metabolites Chemical shift Control-nicotine
(ppm) VIPa Loadingb
Cystine 3.36 5.83 −0.354
Arginine 3.76 2.90 +0.217
Glucose 3.40 2.52 −0.074
Glutamate 2.04 2.06 +0.156
3-Hydroxybutyric acid 1.20 2.05 −0.151
Uracil 7.52 2.03 −0.151
NAD 8.84 1.99 −0.150
Acetone 2.24 1.92 +0.145
Phosphocholine 4.16 1.83 +0.135
L-Phenvlalanine 3.12 1.80 −0.133
aVariable importance in the projection (VIP ≥ 1) was obtained from OSC-PLS.
bLoading: the positive (+) value represents an increase of the metabolite in the
second group of the subtitle (e.g.: Control→ Nicotine), while the negative (−)
value represents a decrease of the metabolite in the second group of
the subtitle.
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It is reported that nicotine is closely bound up with oxi-
dative stresss [35]. Glutathione, creatine and taurine,
which are ubiquitous and important antioxidant, protect
mitochondria against endogenous oxygen radicals [36].
In our present study, these substances in brain were sig-
nificantly altered by nicotine.
Glutathione, one of the most abundant intracellular
antioxidants in the brain, can modulate the activity of
NMDARs [37]. In our study, glutathione in hippocam-
pus displayed a low level in nicotine-induced CPP mice,
implying the weakened antioxidative capability due to
the decrease in glutathione.Table 4 Summary of the variations from striatum
metabolites in mice
Metabolites Chemical shift Control-nicotine
(ppm) VIPa Loadingb
Cystine 3.36 10.51 −0.76
Glucose 3.40 5.97 −0.43
Glutamate 2.08 3.37 −0.18
Acetoacetic acid 3.44 2.02 −0.124
Tryptophan 3.48 1.92 −0.138
Lysine 1.36 1.91 ±0.03
Taurine 3.28 1.54 −0.08
Creatine 3.04 1.49 ±0.088
Acetylcholine 3.24 1.36 ±0.054
NAA 4.4 1.36 ±0.095
aVariable importance in the projection (VIP ≥ 1) was obtained from OSC-PLS.
bLoading: the positive (+) value represents an increase of the metabolite in the
second group of the subtitle (e.g.: Control→ Nicotine), while the negative(−)
value represents a decrease of the metabolite in the second group of
the subtitle.Creatine is thought to have a multifaceted role in the
brain. In addition to being involved in brain osmoregulation,
it has recently been related with energy homeostasis and dir-
ect antioxidant effects [38,39]. We found that creatine was
significantly decreased in hippocampus but increased in stri-
atum by nicotine. As creatine can store energy for the cell,
the alterations of creatine in hippocampus and striatum sug-
gest an energetic shift in different brain regions.
Taurine, a neuroprotective amino acid, has been re-
ported to be a neuroprotective agent in numerous inves-
tigations [40]. It acts as a free radical scavenger, possesses
cytoprotective abilities and prevents the damage from oxi-
dative stress and apoptosis induced by toxicants in various
cells and tissues [41]. In our study, taurine in hippocam-
pus and striatum showed a remarkable decrease after
nicotine treatment, indicating the disturbances of anti-
oxidative stress in brain.
Taken above, we speculate that nicotine affects brain
antioxidative and energy storage capacity by modulating
glutathione, taurine and creatine levels. The central ner-
vous system may take adaptive measures to prevent the
damage from oxidation by consuming taurine and gluta-
thione, thus resulting in stressful declines of glutathione
and taurine in hippocampus and striatum.
Membrane disruption and mitochondria dysregulation
It has been known that glycerol, phosphocholine and
myo-inositol, acting as precursors for the synthesis of
membrane phospholipids in the cell, exert a critical part
on lipid metabolism [42]. Glycerol has been applied to
investigate membrane phospholipid degradation in brain
homogenates after cerebral ischemia and seizures [43].
The damage of membrane results in release of phospho-
lipids and choline compounds, which are the major head
of phospholipids [44]. Interestingly, we found increases
of glycerol in NAc and phosphocholine in PFC in
nicotine-induced CPP mice. The elevated glycerol and
phosphocholine may reflect an enhanced degradation of
cellular membranes in brain, hinting the disruption in
membrane transportation or barrier function.
NAA is regarded as a biomarker of neuronal viability.
Numerous evidences have indicated that NAA may be
linked with multiple roles in neurons, such as neuronal
metabolic function in mitochondria, myelinogenesis,
osmoregulation [45]. Depletion of NAA is considered to
be a reflection of neuronal loss or dysfunction [46]. In
our present study, NAA in striatum showed an increased
level in nicotine-induced CPP mice, suggesting that
nicotine may be related to neuronal activity and modu-
late mitochondria function [47,48].
Energy metabolism
The brain regulates energy homeostasis by balancing en-
ergy intake, expenditure and storage [49]. Neuronal
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study, several metabolites related to energy metabolism
were markedly modified by nicotine, including glucose,
Lac, creatine, glycine and a-ketoglutaric acid.
NAD has been considered to be a key regulator of me-
tabolism, stress resistance and longevity [51]. Moreover,
NAD and NADH are the components of the central
redox pair within cells and substrates of many dehydro-
genases involved in brain energy metabolism [52]. In
nicotine-induce CPP mice, NAD displayed a significant
reduction in PFC. Addiction is a progress of energy con-
sumption, so the decreased NAD in brain may reflect an
enhanced energy demand induced by nicotine.
Glucose, a primary energy substrate for brain metabol-
ism, plays an important role in energy homeostasis
[53-55]. We found that glucose was decreased in stri-
atum, hippocampus and PFC,but increased in NAc by
nicotine CPP paradigm. Nicotine stimulates brain me-
tabolism, which leads to a significant increase in glucose
transporter densities and local cerebral glucose utilization;
moreover, nicotine can effectively improve learning and
cognitive functions [56,57]. It is reported that cognition is
highly energy dependent and glucose acts as main energy
substrate of neurons [58]. Thinking above, our findings
suggest that nicotine could modulate energy metabolism
in various brain regions.
Ketone bodies (D-3-hydroxybutyrate (3OHB) and acet-
oacetate) serve as an energy source alternative to glucose
for the brain and enter the blood brain barrier by the
monocarboxylate transporter 1 [59]. The proliferation
and metabolic activity of neuroglial cells can be signifi-
cantly enhanced by 3-HB and derivatives [60]. In our
study, 3-HB and acetone were significantly decreased in
PFC, but 3-HB was increased in NAc in nicotine-treated
mice.
It is known that memory formation can increase syn-
aptic transmission and morphological alterations at the
synapse, both of which consume more energy in the
neuron [61,62]. Taken above, it is reasonable to infer
that nicotine-induced changes in these metabolites may
reflect an energetic shift and alteration of energy storage
capacity.
Changes in amino acid metabolism
Amino acid metabolism is extremely complex because
large numbers of metabolites are involved. The disorder
of amino acid metabolism is probably induced by gluco-
neogenesis, proteolysis and oxidative catabolism [63].
Amino acids as substrates are extremely equired for en-
ergy production during infection [64]. It is reported that a
certain of metabolites, including sarcosine, uracil, kynure-
nine, glycerol-3-phosphate, leucine and proline, display a
high level in metastatic prostate cancer and can potentially
be regarded as biomarkers for progressive disease [65].Similarly, we also found that several amino acids were sig-
nificantly altered, including cystine, arginine, isoleucine,
glutamate, lysine and phenylalanine. Because these amino
acids belong to essential amino acids, non-essential amino
acids or amino acid with putative neurotransmitter func-
tion, we speculate that protein metabolism in brain could
be influenced by nicotine due to the alteration of amino
acids.
Conclusion
This study developed nicotine CPP paradigm in C57BL/
6 J mice and applied metabolomics based on 1H NMR
spectroscopy to explore the metabonomic profiling in
four brain regions. We found that several metabolites
were specifically modified by nicotine-induced CPP
mice. The modified metabolites include neurotransmit-
ter, energy source, membrane components and amino
acids, which may be the outcome of the adaptive mea-
sures taken by brain in response to nicotine stimula-
tion. Our results show that nicotine CPP may contribute
to a certain region-specific changes of metabolites and
that global metabolite profiling can provide a new
insight into the mechanism about rewarding effect of
nicotine.
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